Angelica Sette

University of Rome Tor Vergata — Italy

Medicine · Health Sciences

11h-index631citations36works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(14), CAR-T cell therapy research(10), Cancer Immunotherapy and Biomarkers(9), Nanoparticle-Based Drug Delivery(3), Immunotherapy and Immune Responses(3)

Publications36 total

Figure 1 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Figure 2 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Figure 3 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Table 1 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Figure 4 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Figure 5 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Table 2 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
N‐Heterocyclic Carbenes on a III‐V Semiconductor: From Chain Formation to Ordered Monolayers
Angewandte Chemie International Edition·2025· 2 citedOpen Access
N‐Heterocyclische Carbene auf einem III‐V‐Halbleiter: Von Kettenbildung zu geordneten Monolagen
Angewandte Chemie·2025Open Access
Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects
Journal for ImmunoTherapy of Cancer·2025· 8 citedOpen Access
Retraction Note: Development of novel anti-Kv 11.1 antibody-conjugated PEG–TiO2 nanoparticles for targeting pancreatic ductal adenocarcinoma cells
Journal of Nanoparticle Research·2025Open Access
719 Acasunlimab combined with PD-1 blockade elicits complementary immune-modulatory effects and enhances anti-tumor activity in preclinical models
Regular and Young Investigator Award Abstracts·2024Open Access
Double-pentagon silicon chains in a quasi-1D Si/Ag(001) surface alloy
Nature Communications·2024Open Access
1181 GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody<sup>®</sup>-CD40x4–1BB), exhibits <i>in vivo</i> antitumor activity and peripheral immune modulation
Regular and Young Investigator Award Abstracts·2023Open Access
Abstract 3283: GEN1046 (DuoBody®-PD-L1x4-1BB) in combination with PD-1 blockade potentiates anti-tumor immunity
Cancer Research·2023
Supplementary Figure from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2023Open Access
Data from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2023Open Access
Data from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2023Open Access
Supplementary Figure from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2023Open Access
Correction to: Development of novel anti-Kv 11.1 antibody-conjugated PEG–TiO2 nanoparticles for targeting pancreatic ductal adenocarcinoma cells
Journal of Nanoparticle Research·2022· 1 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Maria Jure‐Kunkel(16), Alexander Muik(15), Saskia M. Burm(15), Theo S. Plantinga(15), Aras Toker(15), Mark Fereshteh(15), Tahamtan Ahmadi(15), Uğur Şahin(15), Jordan M. Blum(13), Özlem Türeci(13), Elena Garralda(12), Işıl Altıntaş(12), Friederike Gieseke(12), Ravit Geva(12), Eytan Ben‐Ami(12), Corinne Maurice‐Dror(12), Emiliano Calvo(12), Patricia LoRusso(12), Guzmán Alonso(12), María E. Rodríguez-Ruiz(12)